| Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin receptor blocker. | |
| | |
MedLine Citation:
|
PMID: 17414228 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The present study was designed to determine whether adding amlodipine further improved functional and structural cardiovascular damage in hypertensive patients whose blood pressure was already well controlled with an angiotensin II type 1 receptor blocker (ARB). The cardiothoracic ratio on chest radiographs, level of urinary albumin excretion, pulse wave velocity (PWV), intima-media thickness (IMT) of the carotid arteries, and 24 hour ambulatory blood pressure (BP) were evaluated before and 12 months after the start of add-on of amlodipine or placebo in 50 hypertensive patients being treated with an ARB. The add-on amlodipine therapy significantly improved the PWV from 1689 +/- 61 to 1447 +/- 47 cm/s and the IMT from 0.88 +/- 0.08 to 0.75 +/- 0.06 mm in the hypertensive patients treated with an ARB without altering their mean 24 hour ambulatory BP values, but did not alter the cardiothoracic ratio or urinary albumin excretion. Amlodipine also significantly decreased the variability of ambulatory BP, but the decrease did not significantly contribute to the changes in PWV or IMT. Thus, the add-on low-dose amlodipine therapy had benefits in terms of the vascular function and vascular structure of hypertensive patients treated with an ARB that were independent of its depressor effects. The antiatherogenic pleiotropic properties of amlodipine have a preventive effect on the progression of arterial stiffness in hypertensive patients treated with an ARB. |
| | |
Authors:
|
Atsuhiro Ichihara; Yuki Kaneshiro; Mariyo Sakoda; Tomoko Takemitsu; Hiroshi Itoh |
Related Documents
:
|
16500508 - Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population b... 19516168 - Facts and fallacies of blood pressure control in recent trials: implications in the man... 1974508 - Efficacy and safety of carvedilol in renal hypertension. a multicenter open trial. 15923818 - Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy... 10490148 - Transfer function analysis of the circulation in patients undergoing sevoflurane anesth... 8859938 - Vasoconstriction to polymorphonuclear leukocytes in the isolated, perfused rabbit heart... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of cardiovascular pharmacology Volume: 49 ISSN: 0160-2446 ISO Abbreviation: J. Cardiovasc. Pharmacol. Publication Date: 2007 Mar |
Date Detail:
|
Created Date: 2007-04-06 Completed Date: 2007-05-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7902492 Medline TA: J Cardiovasc Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 161-6 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. atzichi@sc.itc.keio.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Albuminuria
/
drug therapy Amlodipine / therapeutic use* Angiotensin II Type 1 Receptor Blockers / therapeutic use* Antihypertensive Agents / therapeutic use* Blood Pressure / drug effects Blood Pressure Monitoring, Ambulatory Carotid Arteries / drug effects*, pathology Drug Therapy, Combination Female Humans Hypertension / drug therapy* Male Middle Aged Pulsatile Flow Radiography, Thoracic Tunica Intima / drug effects Tunica Media / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 88150-42-9/Amlodipine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Role of Na+/H+ exchanger in the pathogenesis of ischemic acute renal failure in mice.
Next Document: Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspiri...